企業所需要的優秀人才，必須具備「能力條件」與「人格特質」兩個面向條件，這是所有現代化企業都同意的觀點，然而，這兩個大面向均為籠統的概念，能否展開到更具體的、甚至有客觀衡量標準的要項，而且在不同階段都可能成為影響工作表現的關鍵因子。各企業間就有相當大的差異，甚至連企管學界的說法也都莫衷一是。因此，如何歸納出最重要的幾個判斷項目？要如何判讀？成為所有組織任用人的關鍵。 本文嘗試以個案研討的方式，說明個案公司如何基於其企業的特質與經營模式，如何透過擷取認知神經科學的學理，彙整出一套系統化的「讀人識人模式」，並輔以問卷調查的深度訪談，針對使用該模式的高階主管，印證該模式的實用性、不足與侷限處，嘗試了解系統化的建構一套判讀人的能力潛質與人格特質之可行性。

甲基安非他命是一種被廣泛濫用的非法神經興奮劑，而且使用之後常伴隨著精神疾病的發生，動物研究也顯示，施打甲基安非他命所引起的神經毒性不僅會造成多巴胺神經元及血清素神經元的損傷，也引起認知功能和社交行為的缺失，同時對於產生迷幻作用的5-HT2A受體作用劑的行為反應增強。N,N,N-trimethylglycine (TMG)和N,N-dimethylglycine (DMG)是甘胺酸的甲基化衍生物，由於這兩種藥物具有治療神經系統疾病的潛力，因此本研究的目的為評估TMG及DMG是否可以預防或改善小鼠在甲基安非他命的暴露下所導致的行為缺失包括新位置辨識測試，新物體辨識測試，社交行為互動測試以及使用5-HT2A受體作用劑DOI 誘導小鼠頭部抽搐(head twitch )的行為。實驗方式為腹腔注射給予雄性ICR小鼠甲基安非他命，一天注射四劑（4 × 5mg/kg），每劑間隔兩小時。實驗一，小鼠在暴露甲基安非他命，先確認行為改變後，給予腹腔注射TMG及DMG (10或30 mg/kg)連續七天，評估TMG及DMG的治療效果。實驗二在施打每劑甲基安非他命30分鐘前給予TMG及DMG (100 mg/kg)，七天後進行行為評估，實驗三，評估TMG及DMG個別及混合劑量的治療效果，小鼠給予甲基安非他命之後，先確認行為改變，再給予腹腔注射TMG及DMG (20、5+5或是10+10 mg/kg) 連續七天，七天後進行行為測試。實驗四，檢測TMG及DMG的治療效果是否藉由活化NMDA受體glycine binding site，小鼠給予甲基安非他命七天之後，腹腔注射TMG及DMG (20 mg/kg)並在給予TMG及DMG前30分鐘給予glycine binding site 拮抗劑7-chlorokynurenic acid (7-CK) (1 mg/kg)，連續給藥七天，七天後進行行為評估。實驗結果發現連續給予七天TMG及DMG在個別劑量及混合劑量中都能夠恢復甲基安非他命所造成的認知功能缺損，社交退縮和降低由DOI 誘導小鼠頭部抽搐行為表現，以及在紋狀體中酪氨酸羥化酶的蛋白質表達減少情況。而前給予7-CK則阻斷TMG及DMG對甲基安非他命所造成的認知功能缺損，社交退縮的改善作用，但是對TMG及DMG對DOI 誘導小鼠頭部抽搐的行為的改善作用影響較小，顯示TMG及DMG可能都是經由活化NMDA 受體的glycine binding site改善甲基安非他命所造成的認知功能缺損，社交退縮，這些發現表示，TMG及DMG具有治療甲基安非他命成癮者所造成的精神分裂等異常症狀的潛力。 / Methamphetamine (METH) is a widely abused illicit psychostimulant. METH use is commonly associated with psychosis. A neurotoxic regimen of METH, which damages the dopaminergic and serotonergic neurons, causes cognitive dysfunction, social interaction deficits, and supersensitivity to hallucinogen in mice. N,N,N-trimethylglycine (TMG) and N,N-dimethylglycine (DMG) are methyl derivatives of amino acid glycine and naturally occur as intermediate metabolites in choline-to-glycine metabolism. Growing evidence shows that both compounds have potential to treat some neurological disorders. The aim of this study was to examine the protective and therapeutic effects of TMG and DMG on METH-induced behavioral aberrations. The novel location recognition test (NLRT), the novel objective recognition test (NORT), the social interaction and the hallucinogenic 2, 5-dimethoxy-4-iodoamphetamine (DOI)-induced head twitch response were evaluated. Male ICR mice received one day drug treatment with four injections of METH (4 × 5 mg/kg, i.p.) or saline at 2h interval. First, TMG or DMG (10 or 30 mg/kg, i.p.) were separately administered once daily for seven consecutive days after the behavioral impairment was confirmed in METH-treated mice. Seven days after final injection of TMG and DMG, the behavioral tests were monitored. Secondly, the preveting effects of TMG and DMG were examined by TMG and DMG (100 mg/kg, i.p.) pretreatment, 30 min prior to each dose of METH. Third, the lower dose (20 mg/kg) and combined effects of TMG and DMG (5+5 or 10+10 mg/kg i.p.) were evaluated. Fourth, in order to determine if the improving effects of TMG and DMG are mediated by NMDA receptor glycine binding site, the glycine binding site antagonist 7-CK (1 mg/kg, i.p.) was administered 30 min prior to each dose of TMG and DMG (20 mg/kg, i.p.), TMG and DMG dose-dependently improved, but not prevented the METH-induced cognition deficits, social withdrawal and hypersensitivity to hallucinogen with additional effect. Pretreatment of 7-CK, reversed the improving effects of TMG and DMG on behavioral deficits after METH exposure, yet had minor effect on hypersensitivity to hallucinogen. These results demonstrate that TMG and DMG might activate the glycine binding site of NMDA receptor to improve METH-induced cognition deficits and social withdrawal. TMG and DMG may be the novel therapeutic agents for psychiatric disorders related to METH abuse.

本研究以心理興奮性藥物(psychosimulants)引發之行為致敏化作為探討環境與藥物的配對學習如何影響個體長期使用藥物後對藥物的反應。首先於實驗一建立安非他命引發自發活動致敏化基本模式，以及不同的重複注射情境下致敏化的表現，結果顯示經由本實驗操弄注射情境的程序可有效引發在測試箱、飼養籠，和第三處的安非他命致敏化表現，並且致敏化自發活動表現量在測試箱組顯著高於飼養籠組和第三處組。實驗二對致敏化形成歷程中可能與安非他命配對的刺激進行消除，以釐清致敏化形成歷程中連結學習的要素，結果顯示消除程序沒有降低致敏化活動量的效果。實驗三使用中樞注射麩胺酸受體拮抗劑NBQX於依核以影響致敏化的連結學習歷程，結果顯示該操弄可阻斷在飼養籠重複注射安非他命引發的行為致敏化。測試箱組經過該操弄後其致敏化活動量顯著降低但仍有顯著的致敏化活動量表現。實驗四分別破壞前額葉皮質兩處次級區塊以瞭解其在致敏化連結學習歷程中扮演的角色，結果顯示破壞背側前額葉皮質只阻斷在飼養籠注射安非他命所引起的行為致敏化，破壞腹側前額葉皮質只阻斷測試箱組行為致敏化。綜合上述研究結果顯示安非他命引發致敏化的形成深受藥物配對的環境影響而可區分環境相依與環境獨立之行為致敏化，環境相依行為致敏化的行為機制可由場合建立的觀點加以解釋。在依核內之麩胺酸傳導和前額葉皮質次級區塊之功能在兩種行為致敏化上的差異可以反應環境相依和環境獨立行為致敏化的潛在神經機制可能有所不同。 / The present study investigated the neurobehavioral mechanisms of d-amphetamine (AMP) induced behavioral sensitization, with the aim to elucidate the role of associative learning between the context and drug. Experiment 1 compared the sensitization effects of repeated (AMP) conducted in three different contexts by the measurement of locomotion activity. The results showed that behavioral sensitization of locomotion was significantly induced AMP repeatedly injected in each of the contexts. However, the magnitudes of behavioral sensitization were different among those three conditions. The highest degree of sensitized locomotion was observed in the group with repeated AMP conducted in the test box in comparing to the other two groups with drug administration in the home cage and a third place, Experiment 2 was designed to examine the effects of extinction on the injection procedure and the contextual cue on the behavioral sensitization of AMP induced in the test box, the home cage, and a third place. The resu lts clearly indicate all three types of locomotion sensitization were resistant to the manipulation of extinction. Experiment 3 tested the effects of NBQX, a glutamatergic AMPA receptor antagonist, infused into the nucleus accumbens on the establishment of behavioral sensitization of AMP induced in the test box and the home cage. This intra-accumbens NBQX treatment significantly suppressed the formation of behavioral sensitization of AMP induced in the home cage, but not in the test box. Experiment 4 investigated the lesion effects of medial prefrontal cortex (mPFC) on the establishment of behavioral sensitization of AMP induced in the test box and the home cage. Two subareas of the mPFC, dorsal and ventral parts, were lesioned by ibotenic acid. The findings indicated a double dissociation existing in the mPFC subareas for the behavioral sensitization of AMP induced in different contexts. The lesion of ventral mPFC inhibited the formation of behavioral sensitization of AMP induced in the test box, whereas the lesion of dorsal mPFC attenuated the AMP sensitization induced at the home cage. Together, these data suggest that the association of the repeated drug effects pairing to the context is critical for the development of behavioral sensitization. Such sensitization can further be differentiated into the context-depentdent and context-independent forms based on the uniqueness of contextual cue in the environment where drug is administered. Different neural substrates are involved in the establishment of behavioral sensitization of AMP.

周邊注射安非它命能夠影響動物受試在表現與時間知覺有關的操作式制約行為作業，歷來被研究者認為是大腦多巴胺神經系統與動物時間知覺系統有關的主要證據之一。本研究所共同採用的研究方法為先注射多巴胺受體專屬拮抗劑再於大鼠受試周邊腹腔注射安非它命的方式探討安非它命影響大鼠時間知覺的大腦機制為何。實驗一利用區辨性增強低頻反應作業觀察周邊注射多巴胺受體專屬拮抗劑何者可以反制周邊安非它命對此作業的影響效果，結果發現多巴胺D1受體拮抗劑SCH23390與D2受體拮抗劑raclopride均可反制周邊安非它命的效果。實驗二同樣利用區辨性增強低頻反應作業，但是將SCH23390與raclopride分別注入海馬迴、背側中區紋狀體、腹側側邊紋狀體、依核、內側前額葉皮質以及腹側頂蓋區等六個部位，觀察何種多巴胺受體拮抗劑可在那些大腦部位產生反制周邊安非它命的效果。結果發現SCH23390可在海馬迴、依核、內側前額葉皮質以及腹側頂蓋區等四個部位產生反制周邊安非它命的效果，而raclopride可在腹側側邊紋狀體與內側前額葉皮質兩個部位產生同樣的反制效果。實驗三利用高峰時距作業觀察SCH23390在海馬迴與內側前額葉皮質是否能反制周邊安非它命對此作業的影響效果，結果發現SCH23390僅在海馬迴會影響大鼠受試的正常表現，特別是在與周邊安非它命同時注射的時候。綜合以上結果顯示，周邊注射安非它命能夠使大鼠受試在區辨性增強低頻反應作業當中表現出時間知覺變快的傾向，這個效果需要同時透過大腦內的海馬迴、依核、內側前額葉皮質以及腹側頂蓋區的多巴胺D1類受體和腹側側邊紋狀體與內側前額葉皮質的多巴胺D2類受體。 / The central dopaminergic system has been hypothesized to play a role in time perception based on the results that peripheral injections of d-amphetamine alter the responses in time-related operant conditioned behavioral tasks. The present study investigated the effect by injecting specific dopamine receptor antagonists before peripheral d-amphetamine injections in rats. Data from Experiment I showed that both peripheral the dopamine receptor D1 antagonist SCH23390 and D2 antagonist raclopride could attenuate the response alteration on differential reinforcement of low-rates responding task induced by peripheral d-amphetamine. By using the DRL task, Experiment 2 employed the microjeciton technique to determine the neural substrates for the DA receptor antagonist to attenuate the effect of peripheral d-amphetamine. The infusion sites for DA receptor antagonist were the hippocampus, the dorsomedial striatum, the ventrolateral striatum, the nucleus accumbens, the medial prefrontal cortex, and the ventral tegme ntal area. The results showed that SCH23390 infused into the hippocampus, the nucleus accumbens, the medial prefrontal cortex, the ventral tegmental area could attenuate the effect induced by peripheral d-amphetamine, and such attenuation effects were also observed for raclopride infused into the ventrolateral striatum, the medial prefrontal cortex. Experiment 3 tried to confirm the results of Experiment 2 by microinjecting SCH23390 in hippocampus and medial prefrontal cortex under peak-interval task. Only SCH23390 in the hippocampus altered the subject's normal performance in this task especially when combined with peripheral injection of d-amphetamine. In conclusion, that the response alteration on the DRL task induced by peripheral injection ofd-amphetamine suggests the subject's timing perception being accelerated. These effects of d-amphetamine were mediated by simultaneous activation of multiple dopamine receptor subtypes including D1 receptors located in the hippocampus, nucleus accumbens, medial pref rontal cortex, ventral tegmental area, as well as D2 receptors located in the ventrolateral striatum, medial prefrontal cortex.